Skip to main content
OpenTrials
Completed

NCT Number: NCT06569992

Etiology and Hemodynamic Instability in Brain Death

Brain death is a complex and irreversible condition marked by the cessation of all brain activity. This retrospective study analyzes ICU patients who progressed from initial brain injury to brain death. The research focuses on demographic profiles, pharmacological interventions, laboratory data, and imaging findings to understand these cases clinical trajectories and therapeutic responses. Central to this study is evaluating cardiovascular support using the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure (TIE) Score. This study explores the relationship between the etiology of brain death and the pharmacologic cardiovascular support administered, as quantified by VIS and TIES scores. This study seeks to enhance the management strategies and improve outcomes for patients diagnosed with brain death

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Health Sciences

Antalya, Muratpasa, 07100, Turkey (Türkiye)

About this study

This study undertakes a comprehensive retrospective analysis of patients admitted to the intensive care unit (ICU) with an initial diagnosis of brain injury who subsequently progressed to brain death. The investigation will meticulously assess these patients, demographic profiles, pharmacological interventions, laboratory parameters, and radiological imaging findings. The overarching aim is to delineate the clinical trajectory and therapeutic responses of patients diagnosed with brain death, critically evaluating the complexities encountered during their management, and providing evidence-based insights to inform future treatment protocols.

Central to this study is the quantitative assessment of hemodynamic stability using the Vasoactive-Inotropic Score (VIS) and the Total Inotrope Exposure (TIE) Score. The VIS will quantify the need for vasopressor and inotropic support, reflecting the severity of cardiovascular instability. At the same time, the TIE Score will measure the cumulative exposure to inotropic agents, providing a comprehensive evaluation of the overall cardiovascular burden. The primary aim of this study is to explore the relationship between the etiology of brain death and the pharmacologic cardiovascular support administered, as quantified by VIS and TIES scores. Additionally, the study will assess how these pharmacologic interventions differ in patients who have undergone decompressive surgery compared to those who have not.

This thesis aspires to make a significant contribution to the optimization of management strategies for patients diagnosed with brain death, aiming to enhance clinical decision-making and improve patient outcomes in this critically ill cohort.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (≥18 years) admitted to the intensive care unit (ICU) at Antalya Training and Research Hospital between 2019 and 2023.
  • Patients with a confirmed diagnosis of brain death based on a positive apnea test and/or neuroimaging findings.
  • Patients with comprehensive and complete clinical data available in the hospital's medical records.

Exclusion criteria

  • Patients under the age of 18.
  • Patients with incomplete clinical data in the medical records.
  • Patients with moderate to severe heart failure.
  • Patients with major organ injuries in addition to traumatic intracranial hemorrhage.
  • Pregnant patients.
  • Patients with significant comorbidities that could impact hemodynamic stability.
  • Patients experiencing hemodynamic instability due to septic shock.
  • Patients who were initially treated for brain injury at external facilities and later transferred to our hospital.

Treatment and study plan

VIS, TIES

Other

The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.

Primary outcomes

  1. Total Inotrope Exposure Score (TIES)

    Time frame: From beginning to vasoactive-inotropic drugs infusion until diagnosis of brain death, 10 days (with intermediate measurements every hours)

    Dopamine dose (μg/kg/min) × [length of administration in days] + Dobutamine dose (μg/kg/min) × [length of administration in days] + 10 × Milrinone dose (μg/kg/min) × [length of administration in days] + 100 × Epinephrine dose (μg/kg/min) × [length of administration in days] + 100 × Norepinephrine dose (μg/kg/min) × [length of administration in days] + 10,000 × Vasopressin dose (U/kg/min) × [length of administration in days

  2. Vasoactive-Inotropic Score (VIS)

    Time frame: From beginning to vasoactive-inotropic drugs infusion until diagnosis of brain death, 10 days (with intermediate measurements every hours)

    Dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min) + 10 × milrinone dose (μg/kg/min) + 10 000 × vasopressin dose (unit/kg/min) + 100 × norepinephrine dose (μg/kg/min).

Sponsors and collaborators

Lead sponsor

Antalya Training and Research Hospital

Other Gov

Registry information

Official study title

Comparison of the Relationship Between Etiology and Hemodynamic Instability in Brain Death: VIS and TIES

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Aug 26, 2024
Registry last updated
Feb 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.